AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
AIM Vaccine Co., Ltd. has successfully completed Phase III clinical trials for its 13-valent pneumonia conjugate vaccine and obtained a production license, positioning the company to become a key supplier in a market with significant growth potential in China. The vaccine targets infants and young children and addresses an underserved global demand of 180 million doses, with China’s market projected to expand substantially by 2030.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.